Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-01-26
DOI
10.3389/fphar.2020.621093
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors
- (2020) Oliver Bechter et al. PHARMACOLOGY & THERAPEUTICS
- MYC’s Fine Line Between B Cell Development and Malignancy
- (2020) Oriol de Barrios et al. Cells
- Long non-coding RNA UCA1 modulates cell proliferation and apoptosis by regulating miR-296-3p/Myc axis in acute myeloid leukemia
- (2020) Jiajia Li et al. CELL CYCLE
- Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation
- (2020) Omer Gilan et al. SCIENCE
- Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
- (2020) V. Moreno et al. ANNALS OF ONCOLOGY
- First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
- (2020) Malaka Ameratunga et al. BRITISH JOURNAL OF CANCER
- First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.
- (2019) Judy Sing-Zan Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Bromodomains: a new target class for drug development
- (2019) Andrea G. Cochran et al. NATURE REVIEWS DRUG DISCOVERY
- Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
- (2019) Yingyao Zhou et al. Nature Communications
- Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
- (2019) Gerald S. Falchook et al. CLINICAL CANCER RESEARCH
- First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
- (2019) Sarina A. Piha-Paul et al. CLINICAL CANCER RESEARCH
- Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies
- (2019) Manish R. Patel et al. BLOOD
- 41OA phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma
- (2018) K A Blum et al. ANNALS OF ONCOLOGY
- BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo
- (2018) Mary A. Morse et al. ANTIVIRAL RESEARCH
- Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
- (2018) Jeremy Lewin et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of p53/miR-155-5p/sirt1 loop in renal tubular injury of diabetic kidney disease
- (2018) Yue Wang et al. Journal of Translational Medicine
- Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.
- (2018) Amita Patnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- 411OInitial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer
- (2018) J Hilton et al. ANNALS OF ONCOLOGY
- BRD4 and Cancer: going beyond transcriptional regulation
- (2018) Benedetta Donati et al. Molecular Cancer
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors
- (2016) C. Massard et al. EUROPEAN JOURNAL OF CANCER
- The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
- (2016) Yasushi Taniguchi INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- Functions of BET proteins in erythroid gene expression
- (2015) Aaron J. Stonestrom et al. BLOOD
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data
- (2015) Lesley A. Stewart et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Chromatin-Dependent Role of the Fragile X Mental Retardation Protein FMRP in the DNA Damage Response
- (2014) Roman Alpatov et al. CELL
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond
- (2014) Eric Verdin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Bromodomain and Extraterminal (BET) Protein Inhibition Suppresses Human T Cell Leukemia Virus 1 (HTLV-1) Tax Protein-mediated Tumorigenesis by Inhibiting Nuclear Factor κB (NF-κB) Signaling
- (2013) Xuewei Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
- (2013) Z Zou et al. ONCOGENE
- BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domain
- (2012) B. N. Devaiah et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bromodomains as therapeutic targets
- (2011) Susanne Muller et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3
- (2011) S. Rahman et al. MOLECULAR AND CELLULAR BIOLOGY
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Brd4 Coactivates Transcriptional Activation of NF- B via Specific Binding to Acetylated RelA
- (2008) B. Huang et al. MOLECULAR AND CELLULAR BIOLOGY
- The Double Bromodomain Proteins Brd2 and Brd3 Couple Histone Acetylation to Transcription
- (2008) Gary LeRoy et al. MOLECULAR CELL
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started